Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?)

Am J Cardiol. 2008 May 1;101(9):1364-6. doi: 10.1016/j.amjcard.2007.12.039. Epub 2008 Mar 7.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Clinical Trials, Phase III as Topic
  • Clopidogrel
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Multicenter Studies as Topic
  • Myocardial Infarction / drug therapy*
  • Piperazines / therapeutic use*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prasugrel Hydrochloride
  • Randomized Controlled Trials as Topic
  • Thiophenes / therapeutic use*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use
  • Treatment Outcome

Substances

  • Piperazines
  • Platelet Aggregation Inhibitors
  • Thiophenes
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticlopidine